4D Molecular Therapeutics (NASDAQ:FDMT) Insider David Kirn Sells 58,333 Shares

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider David Kirn sold 58,333 shares of the stock in a transaction on Monday, September 14th. The stock was sold at an average price of $13.90, for a total value of $810,828.70. Following the completion of the sale, the insider owned 767,486 shares in the company, valued at approximately $10,668,055.40. The trade was a 7.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

David Kirn also recently made the following trade(s):

• On Monday, August 3rd, David Kirn sold 12,415 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.05, for a total transaction of $124,770.75.
• On Friday, July 10th, David Kirn sold 15,725 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.03, for a total transaction of $189,171.75.
• On Thursday, July 9th, David Kirn sold 42,608 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.87, for a total transaction of $548,364.96.
• On Monday, June 22nd, David Kirn sold 114,746 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.47, for a total transaction of $1,201,390.62.

4D Molecular Therapeutics Trading Up 1.0%

Shares of FDMT opened at $13.76 on Thursday. 4D Molecular Therapeutics, Inc. has a 1-year low of $6.47 and a 1-year high of $16.93. The company has a 50-day moving average of $12.70 and a 200 day moving average of $10.78. The firm has a market capitalization of $760.10 million, a price-to-earnings ratio of -5.23 and a beta of 2.74. The company has a debt-to-equity ratio of 0.05, a current ratio of 8.03 and a quick ratio of 8.03.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings data on Thursday, August 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). The company had revenue of $3.78 million during the quarter, compared to analysts’ expectations of $3.62 million. 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. On average, research analysts expect that 4D Molecular Therapeutics, Inc. will post -4.07 EPS for the current year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Several hedge funds have recently modified their holdings of the business. Jupiter Topco LLC purchased a new position in 4D Molecular Therapeutics during the second quarter valued at approximately $76,466,000. Janus Henderson Group PLC lifted its holdings in 4D Molecular Therapeutics by 13.2% during the first quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company’s stock worth $48,868,000 after buying an additional 611,276 shares during the period. BlackRock Inc. purchased a new stake in 4D Molecular Therapeutics during the second quarter worth $60,463,000. Trails Edge Capital Partners LP bought a new stake in 4D Molecular Therapeutics during the 2nd quarter valued at $29,631,296. Finally, Armistice Capital LLC boosted its position in 4D Molecular Therapeutics by 76.6% during the 4th quarter. Armistice Capital LLC now owns 1,936,000 shares of the company’s stock valued at $14,520,000 after acquiring an additional 840,000 shares in the last quarter. Hedge funds and other institutional investors own 99.27% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $32.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday, August 13th. B. Riley Financial reiterated a “buy” rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. Cantor Fitzgerald raised 4D Molecular Therapeutics from a “neutral” rating to an “overweight” rating and set a $20.00 price target on the stock in a research report on Monday. Finally, Chardan Capital upgraded 4D Molecular Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $28.56.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company developing genetic medicines for serious diseases with significant unmet medical needs. The company uses its Therapeutic Vector Evolution platform to engineer and select adeno-associated virus (AAV) vectors designed to deliver genetic payloads to specific tissues and support the development of potentially durable, one-time treatments.

Its research and development programs have focused primarily on ophthalmic and pulmonary diseases.